Education
About Us
Working with TipRanks
Follow Us
Nymox Pharmaceutical (NYMXF)
OTHER OTC:NYMXF
| Dec 24 | Dec 23 | Mar 23 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | - |
| Gross Profit | $ -1.00K | $ -11.00K | $ -12.00K | $ -12.00K | - |
| Operating Income | $ -4.28M | $ -8.35M | $ -6.65M | $ -12.50M | $ -11.72M |
| EBITDA | $ -4.26M | $ -8.77M | $ -6.52M | $ -12.49M | $ -11.71M |
| Net Income | $ -4.49M | $ -8.84M | $ -6.58M | $ -12.54M | $ -11.74M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 74.00K | $ 70.00K | $ 1.40M | $ 830.00K | $ 3.61M |
| Total Assets | $ 654.00K | $ 627.00K | $ 1.63M | $ 2.03M | $ 4.93M |
| Total Debt | $ 0.00 | $ 750.00K | $ 173.00K | $ 391.00K | $ 426.00K |
| Net Debt | $ -74.00K | $ 680.00K | $ -1.23M | $ -439.00K | $ -3.19M |
| Total Liabilities | $ 7.43M | $ 3.80M | $ 2.11M | $ 1.95M | $ 2.20M |
| Stockholders' Equity | $ -6.78M | $ -3.17M | $ -482.00K | $ 83.00K | $ 2.73M |
| Cash Flow | |||||
| Free Cash Flow | $ -2.60M | $ -4.06M | $ -5.21M | $ -9.83M | $ -10.05M |
| Operating Cash Flow | $ -2.60M | $ -4.06M | $ -5.21M | $ -9.82M | $ -10.04M |
| Investing Cash Flow | $ 0.00 | $ -3.00K | $ 0.00 | $ -6.00K | $ -13.00K |
| Financing Cash Flow | $ 2.60M | $ 2.73M | $ 5.78M | $ 7.04M | $ 8.42M |
Nymox Pharmaceutical Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.